Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q1 FY24 results · Apr–Jun 2023
Natco Pharma reported revenue from operations of ₹1,140.50 crore (up 28.9% from Q1 FY23) and net profit of ₹420.30 crore (up 31.2% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,140.50 | 884.60 | +28.9% | 897.90 | +27.0% |
| Other income | 19.70 | 34.30 | −42.6% | 29.00 | −32.1% |
| Total income | 1,160.20 | 918.90 | +26.3% | 926.90 | +25.2% |
| Profit before tax | 500.00 | 385.80 | +29.6% | 324.40 | +54.1% |
| Net profit for the period | 420.30 | 320.40 | +31.2% | 275.80 | +52.4% |
| EPS, basic (₹) | 23.26 | 17.55 | +32.5% | 15.11 | +53.9% |
| Net margin (%) | 36.9 | 36.2 | 30.7 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,048.30 | 805.70 | +30.1% | 781.20 | +34.2% |
| Other income | 14.60 | 33.20 | −56.0% | 17.50 | −16.6% |
| Total income | 1,062.90 | 838.90 | +26.7% | 798.70 | +33.1% |
| Profit before tax | 475.20 | 373.00 | +27.4% | 306.40 | +55.1% |
| Net profit for the period | 405.30 | 308.00 | +31.6% | 254.10 | +59.5% |
| EPS, basic (₹) | 22.43 | 16.87 | +33.0% | 13.92 | +61.1% |
| Net margin (%) | 38.7 | 38.2 | 32.5 |
Consolidated
- Filed with BSE
- 09 Aug 2023, 17:09 IST
- Board meeting
- 09 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Aug 2023, 17:09 IST
- Board meeting
- 09 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE